Cargando…
Point-of-care G6PD diagnostics for Plasmodium vivax malaria is a clinical and public health urgency
Malaria caused by Plasmodium vivax threatens over 2 billion people globally and sickens tens of millions annually. Recent clinical evidence discredits the long-held notion of this infection as intrinsically benign revealing an often threatening course associated with mortality. Most acute attacks by...
Autor principal: | Baird, J. Kevin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4677444/ https://www.ncbi.nlm.nih.gov/pubmed/26652887 http://dx.doi.org/10.1186/s12916-015-0531-0 |
Ejemplares similares
-
Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms
por: Baird, J. Kevin, et al.
Publicado: (2018) -
Origins and implications of neglect of G6PD deficiency and primaquine toxicity in Plasmodium vivax malaria
por: Baird, Kevin
Publicado: (2015) -
Dynamics of G6PD activity in patients receiving weekly primaquine for therapy of Plasmodium vivax malaria
por: Taylor, Walter R. J., et al.
Publicado: (2021) -
Assessing the Operational Feasibility of Integrating Point-of-Care G6PD Testing into Plasmodium vivax Malaria Management in Vietnam
por: Gerth-Guyette, Emily, et al.
Publicado: (2023) -
Management of Plasmodium vivax risk and illness in travelers
por: Baird, J. Kevin
Publicado: (2017)